dc.contributor.author
Schmöcker, Christoph
dc.contributor.author
Zhang, Ingrid W.
dc.contributor.author
Kiesler, Stefanie
dc.contributor.author
Kassner, Ursula
dc.contributor.author
Ostermann, Annika I.
dc.contributor.author
Steinhagen-Thiessen, Elisabeth
dc.contributor.author
Schebb, Nils H.
dc.contributor.author
Weylandt, Karsten-H.
dc.date.accessioned
2018-06-08T10:24:57Z
dc.date.available
2018-04-23T12:13:41.092Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/20392
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-23695
dc.description.abstract
Omega-6 polyunsaturated fatty acid (n-6 PUFA) is the predominant
polyunsaturated fatty acid (PUFA), especially in Western diet. A high
omega-6/omega-3 ratio in Western diets is implicated in the development of
cardiovascular diseases and inflammatory processes. Studies in animal models
and in humans have demonstrated beneficial effects of omega-3 PUFA (n-3 PUFA)
in a variety of diseases, including cardiac arrhythmias and inflammatory
diseases, as well as breast and colon cancer. The molecular mechanisms
underlying the effects of n-3 PUFA are still not well understood. Possible
mechanisms include competition between n-3 and n-6 PUFAs at the cyclooxygenase
(COX) and lipoxygenase (LOX) and cytochrome P450 levels, and subsequent
formation of oxylipins with specific anti-inflammatory or anti-arrhythmic
effects. In this study, we report the impact of routine long-term treatment
with prescription-grade n-3 PUFA (either 840 mg or 1680 mg per day) on blood
cell membrane fatty acid composition, as well as plasma oxylipin patterns, in
a patient population with severe hyperlipidemia and cardiovascular disease who
are on standard lipid-lowering and cardioprotective medications. Lipidomics
analyses were performed by LC/ESI-MS/MS. Supplementation led to a dose-
dependent increase in n-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) in the blood cell fraction. We also observed a dose-dependent
increase in EPA- and DHA-derived epoxy metabolites, whereas the effect of n-3
PUFA supplementation on LOX-dependent EPA- and DHA-derived hydroxy metabolites
was less pronounced, with a tendency towards lower metabolites in subjects
with higher n-3 PUFA levels. These data thus generally confirm effects of n-3
PUFA supplementation observed previously in healthy individuals. Additionally,
they indicate a suppressive effect of high n-3 PUFA supplementation on the
formation of LOX metabolites in the context of concomitant aspirin medication.
en
dc.format.extent
12 Seiten
dc.rights.uri
http://creativecommons.org/licenses/by/4.0/
dc.subject
omega-3 fatty acids
dc.subject
hyperlipidemia
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.title
Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine
Clinical Setting
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation
International Journal of Molecular Sciences 19 (2018), 1, S. 7996-8012
dcterms.bibliographicCitation.doi
10.3390/ijms19010180
dcterms.bibliographicCitation.url
http://doi.org/10.3390/ijms19010180
refubium.affiliation
Charité - Universitätsmedizin Berlin
de
refubium.mycore.fudocsId
FUDOCS_document_000000029617
refubium.note.author
Der Artikel wurde in einer Open-Access-Zeitschrift publiziert.
refubium.resourceType.isindependentpub
no
refubium.mycore.derivateId
FUDOCS_derivate_000000009663
dcterms.accessRights.openaire
open access
dcterms.isPartOf.issn
1661-6596
dcterms.isPartOf.issn
1422-0067